Regeneron high-dose Eylea gains FDA approval (NASDAQ:REGN)
Iryna Drozd The US FDA has approved Regeneron Pharmaceuticals' (NASDAQ:REGN) high-dose ("HD") version of its blockbuster therapy Eylea (aflibercept). The new formulation allows patients to receive treatment less frequently. HD Eylea is…
